{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.","id":"OG000","title":"ALK-positive Solid Tumors"}],"populationDescription":"OS was defined as the time from first dose of study drug to death from any cause- and could not be calculated due to an insufficient number of participants with the event.","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug to death from any cause (up to 5 years)","title":"OS in Participants With Primary CNS Tumors","type":"SECONDARY"}